BioSpace News Archive

Acadia Pharmaceuticals Inc. announced that on August 1, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares of common stock and 14,990 restricted stock units to 16 new employees under Acadia’s 2023 Inducement Plan.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Alaunos Therapeutics, Inc., announced financial results for the second quarter ended June 30, 2023.

Acer Therapeutics Inc. reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”) today announced financial results for the three and six months ended June 30, 2023 and highlighted recent corporate updates.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported financial results for the second quarter ended June 30, 2023.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2023.

GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform and augmented validation protocols to generate immunological reagents against high-value targets that have historically proven difficult to produce.

Neuronetics, Inc. announced enhancements to the TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting system for NeuroStar transcranial magnetic stimulation providers.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX) today announced its financial results for the three months ended June 30, 2023, and other recent developments.